Trial Profile
FIRST Registry: Follow-up in Rivaroxaban Patients in the Setting of Thromboembolism
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 16 Jun 2016
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Therapeutic Use
- 17 Dec 2015 Accrual to date is 10% according to United Kingdom Clinical Research Network.
- 13 Nov 2015 Accrual to date is 9% according to United Kingdom Clinical Research Network.
- 07 Oct 2015 Accrual to date is 8% according to United Kingdom Clinical Research Network.